Disease-modifying drugs for Alzheimer's offer a meaningful glimpse of hope for many people who fear dementia. Alzheimer's disease is the most common cause of dementia, but dementia itself is an umbrella term for symptoms such as memory loss, confusion and changes in thinking.
Unlike older dementia drugs, which help with symptoms but do not change the underlying disease, disease-modifying treatments are designed to slow the disease process itself. So far, these treatments appear to delay symptom progression by several months rather than years. They also carry a small but serious risk of side effects, including swelling and bleeding in the brain. At present, they are suitable only for some people in the early stages of Alzheimer's disease, meaning that many others will still face dementia with no cure on the horizon.
The fact that scientists are now achieving some degree of disease modification has generated enormous interest in dementia research. That attention is essential if these advances are to continue. But public excitement can also narrow the conversation, drawing attention toward the biology of dementia and away from the lives of the people experiencing it.
For many years, social scientists have argued for a broader understanding of dementia. Dementia begins with changes in the brain, but it affects the whole person. It can change how someone remembers, communicates, relates to others and makes sense of the world.
